Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology...
Day: August 17, 2023
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
Fort Lee, NJ, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Nanox Announces Second Quarter of 2023 Financial Results and Provides Business Update
Reports progress towards global supply chain development Ended the second quarter of 2023 with cash, cash equivalents, restricted cash and...
Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primatesData are a key component of...
Good Supply’s Fan Favourite Cannabis Strains Just Got ‘Juiced’
The New Fruit-Forward Infused Pre-Roll Series from Best-Selling Cannabis Brand Good Supply Now Available Across CanadaTORONTO, Aug. 17, 2023 (GLOBE...
Coloplast Finance B.V. – Announcement no. 04/2023 – Interim Financial Report 9M 2022/23
9M 2022/23Interim financial results, 9M 2022/231 October 2022 - 30 June 2023 Coloplast delivered Q3 organic growth of 8% and...
Tonix Pharmaceuticals to Present at the August Virtual Investor Summit
CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products...
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA)...
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer’s Disease
NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Immatics Announces Second Quarter 2023 Financial Results and Business Update
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAMEACTengine® IMA203 TCR-T...
Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per...
G Medical Innovations Will Provide Services to Veterans and Military Personnel by Partnering With Resilient Support Services
Rehovot, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations”), an industry...
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase...
The International Myeloma Foundation (IMF) Welcomes Visionary & Strategic Fundraiser Sylvia Dsouza as Vice President of Philanthropy
A Media Snippet accompanying this announcement is available by clicking the link or image above. LOS ANGELES, Aug. 17, 2023...
Aesthetic Medical International Announces (i) Closing of Share Transfer, Issue of Conversion Shares, and Issue of Warrants, (ii) Resignations and Appointment of Directors, (iii) Release of Share Pledge, and (iv) Entry into certain Contractual Arrangements with respect to Equity Interests
Closing of Share Transfer, Issue of Conversion Shares, and Issue of Warrants Reference is made to the press release of...
Conversion of convertible notes pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and Riverfort Global Opportunities PCC Ltd
BBS-Bioactive Bone Substitutes Plc, Company announcement, 17 August 2023 at 12:00 p.m. Conversion of convertible notes pursuant to financing arrangement...
Advanced Health Intelligence Obtains Overseas R&D Reimbursement Under Australia’s Research and Development Tax Incentive Scheme (R&DTI)
South Perth, Australia--(Newsfile Corp. - August 17, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or the...